Following more than a decade of development and a priority review, Pfizer Inc. has won FDA approval for Daurismo (glasdegib), a new drug that, when used with low-dose cytarabine (LDAC), has been shown to increase overall survival vs. cytarabine alone by a median of about four months for certain patients intolerant of intensive chemotherapy. The regulator also approved a supplemental new drug application in a similar indication for Venclexta (venetoclax), a drug marketed by Abbvie Inc. and Genentech/Roche Holding AG.